Japanese encephalitis virus is an RNA flavivirus that causes virus encephalitis across Asia, the western Pacific region and parts of Australia.
It is transmitted in an enzootic cycle and the virus is transmitted to humans through the bite of infected Culex tritaeniorhynchus mosquitoes.
There is no specific antiviral treatment for Japanese encephalitis virus and management is mainly symptomatic treatment and supportive care.
Personal protection from mosquito bites in endemic areas and obtaining vaccination are the primary strategies to control Japanese encephalitis virus infection due to lack of specific antiviral therapy, high case fatality, and substantial morbidity.
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Consistent with the overall outcome of the phase III EF-14 study, elderly patients with newly diagnosed glioblastoma multiforme (GBM) treated with tumour-treating fields (TTFields) and temozolomide (TMZ) showed significantly better overall survival (OS) vs patients on TMZ alone, according to a post-hoc analysis presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.